DETERMINATION OF ENTACAPONE IN PHARMACEUTICAL FORMULATIONS BY RP-HPLC METHOD

Authors

  • Devika.G.S Department of Pharmaceutical Analysis and Quality Assurance, Vasavi Institute of Pharmaceutical Sciences, Affiliated to JNTUA, Kadapa-516247, Andhra Pradesh, India.
  • Ramesh Petchi Department of Pharmaceutical Analysis and Quality Assurance, Vasavi Institute of Pharmaceutical Sciences, Affiliated to JNTUA, Kadapa-516247, Andhra Pradesh, India.
  • M.Kiran kumar Department of Pharmaceutical Analysis and Quality Assurance, Vasavi Institute of Pharmaceutical Sciences, Affiliated to JNTUA, Kadapa-516247, Andhra Pradesh, India.
  • M.Purushothaman Department of Pharmaceutical Analysis and Quality Assurance, Vasavi Institute of Pharmaceutical Sciences, Affiliated to JNTUA, Kadapa-516247, Andhra Pradesh, India.

Keywords:

Entacapone, RP- HPLC, Tablets, Validation

Abstract

Entacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor for the treatment of Parkinson’s disease. A simple, precise, specific, and accurate reversed phase high performance liquid chromatographic (RP-HPLC) method was developed for the estimation of entacapone in bulk and its pharmaceutical dosage forms. The method was carried out on a X timateTM HPLC C18 (250×4.6 ,5µ) column using a mixture of acetonitrile and 0.02M potassium dihydrogen orthophosphate , pH 6.0 adjusted with dilute tri ethylamine in the ratio of 55:45 at flow rate of 1ml/min with UV detection at 310 nm. System suitability parameters were studied by injecting the standard five times and results were well under the acceptance criteria. Linearity study was carried out between 20 to120  µg/ml , R2 value was found to be as 0.999. The percentage of RSD was found to be lower than 2% proves that the method is precise. The excipients present in the formulations do not interfere with the assay procedure. The proposed HPLC conditions ensure sufficient resolution and the precise quantification of the compounds. Results from statistical analysis of the experimental analysis were indicative of satisfactory precision and reproducibility. Hence the developed method was successfully applied to determine entacapone in pharmaceutical formulations.

Downloads

Download data is not yet available.

References

Budavari S. 12th ed. New Jersey, USA: Merck and Co., Inc; The Merck Index; pp. 1564–3630. 1996.

Martindale . 32nd ed. Great Britain: Council of Royal Pharmaceutical Society of Great Britain; The Complete Drug Reference; p. 1168-1169.1999.

O’Neil MJ. The Merck Index, Merck and Co. Inc., White House Station: NJ, ;3630.2001.

Lyytinen J, Kaakkola S, Gordin A, Kultalahti ER, Teräväinen H. Entacapone and selegiline with -dopa in patients with Parkinson's disease: an interaction studyParkinsonism & Related Disorders.2000. 6 (4): 215-222.

Bugamelli F, Marcheselli C, Barba E, Raggi MA . Determination of L-dopa, carbidopa, 3-O-methyldopa and entacapone in human plasma by HPLC. J Pharm Biomed Anal .2011;54: 562-567.

Doshi AS, Upadhyay KJ, Mehta TN, Nanda N . Development and application of a high- performance liquid chroma-tographic method for the determination of in vitro drug release of levodopa, Carbidopa, and Entacapone from a tablet formulation.JAOAC Int.2011;92: 394-403.

Gadallah MN, Mohamed MS.Determination of anti-parkinsonism drug Entacapone.J. Chil.Chem.Soc. 2010; 55: 85-89.

Paim CS, Martins MT, Malesuik MD, Steppe M . LC determination of entacapone in tablets: in vitro dissolution studies. J ChromatogrSci.2010; 48: 755-759.

Ramakrishna NVS, Vishwottam KN, Wishu S, Koteshwara M, Chidambara J, High-performance liquid chromatography method for the quantification of entacapone in human plasma. J. Chromatogr. B. 2005; 823(2):189-94.

Prafullachandra T, VinayakMS, Pai NR, Chandrabhanu M, TekaleS . Estimation of Entacapone tablets by reverse phase high performance liquid chromatographic method. Bioscience Discovery.2011. 2:294-298.

Prafullachandra T, SmrutiT,Vinayak SM. Determination of impurities in formulated form of entacapone by using rp - hplc method. Der Pharma Chemica .2011;3: 63-68.

Soukhova N, Kassymbek Z, Bradby S, Martin-Esker A, White P, Wahab S. Development of characterization methods for entacapone in a pharmaceutical bulk. J. Pharm. Biomed. Anal. 2011;54(4):860-5.

Paim CS, Gonc HM, Miron D, Sippel J, Steppe M . Stability-indicating LC determination of Entacapone in tab-lets.Chromatographia.2007; 65:595-599.

Issa YM, HassounME, ZayedAG.Application of high performance liquid chromatographic method for the determination of levodopa, carbidopa, and entacapone in tablet dosage forms. Journal of Liquid Chromatography & Related Technologies .2011;34: 2433-2447.

ICH Q2 (R1), Validation of analytical procedures, Text and methodology. International Conference on Harmonization Geneva .1-17;2005.

Published

2016-03-17
Statistics
10 Views | 18 Downloads
Citatons

How to Cite

Devika.G.S, Ramesh Petchi, M.Kiran kumar, and M.Purushothaman. “DETERMINATION OF ENTACAPONE IN PHARMACEUTICAL FORMULATIONS BY RP-HPLC METHOD”. International Journal of Pharmaceutics and Drug Analysis, vol. 4, no. 3, Mar. 2016, pp. 105-11, https://ijpda.com/index.php/journal/article/view/208.

Issue

Section

Research Articles
Share |